Leap Therapeutics, Inc.
LPTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $2 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | $2 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $57 | $73 | $45 | $32 |
| G&A Expenses | $13 | $14 | $12 | $11 |
| SG&A Expenses | $13 | $13 | $12 | $11 |
| Sales & Mktg Exp. | $0 | -$0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $70 | $87 | $57 | $43 |
| Operating Income | -$70 | -$87 | -$57 | -$41 |
| % Margin | – | – | – | -2,761.7% |
| Other Income/Exp. Net | $3 | $6 | $2 | $1 |
| Pre-Tax Income | -$67 | -$81 | -$54 | -$41 |
| Tax Expense | $1 | $0 | $0 | -$0 |
| Net Income | -$68 | -$81 | -$55 | -$41 |
| % Margin | – | – | – | -2,705.8% |
| EPS | -1.81 | -3.98 | -4.82 | -4.73 |
| % Growth | 54.5% | 17.4% | -1.9% | – |
| EPS Diluted | -1.81 | -3.98 | -4.82 | -4.73 |
| Weighted Avg Shares Out | 38 | 20 | 11 | 9 |
| Weighted Avg Shares Out Dil | 38 | 20 | 11 | 9 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $4 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$70 | -$81 | -$54 | -$41 |
| % Margin | – | – | – | -2,702.7% |